Anna Luisa Di Stefano

This study identifies PTEN gain-of-function mutations as linked to increased migratory efficiency in glioblastoma cells, correlating with poorer patient survival.

The paper develops interpretable models to predict cancer drug sensitivity using transcriptomics data and enhances predictions with large language models, validated on clinical samples.

This study identifies BIRC3 as a prognostic biomarker and therapeutic target for TMZ-resistant glioblastoma, validated across multiple datasets and showing efficacy when combined with AZD5582.